Literature DB >> 15206760

Tryptophan pyrrole ring cleavage enzymes in placenta.

Yohsuke Minatogawa1, Sachiko Suzuki, Yoko Ando, Shigenobu Tone, Osamu Takikawa.   

Abstract

Tryptophan pyrrole ring cleavage enzymes were assayed in pregnant uterus of mouse. The highest activity was observed at 6.5 days post-coitus (dpc) with a small activity shoulder at 9.5 to 12.5 dpc concepti and placenta. The highest peak at early concepti of 6.5 dpc was coincided with gene expression of tryptophan 2,3-dioxygenase (TDO). And the shoulder from 9.5 dpc was coincided with the expression of indoleamine 2,3-dioxygenase (IDO). These enzymes showed a different inhibitory behavior to a proper IDO inhibitor, 1-methyl tryptophan. In situ hybridization analysis revealed that TDO was expressed in the decidua of the early concepti. This is the first report of the extra hepatic TDO.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15206760     DOI: 10.1007/978-1-4615-0135-0_50

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  13 in total

1.  Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase.

Authors:  Luc Pilotte; Pierre Larrieu; Vincent Stroobant; Didier Colau; Eduard Dolusic; Raphaël Frédérick; Etienne De Plaen; Catherine Uyttenhove; Johan Wouters; Bernard Masereel; Benoît J Van den Eynde
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

2.  Differential expression and regulation of Ido2 in the mouse uterus during peri-implantation period.

Authors:  Dang-Dang Li; Xin-Yuan Liu; Chuan-Hui Guo; Liang Yue; Zhan-Qing Yang; Hang Cao; Bin Guo; Zhan-Peng Yue
Journal:  In Vitro Cell Dev Biol Anim       Date:  2014-11-19       Impact factor: 2.416

3.  Vascular expression, activity and function of indoleamine 2,3-dioxygenase-1 following cerebral ischaemia-reperfusion in mice.

Authors:  Katherine A Jackman; Vanessa H Brait; Yutang Wang; Ghassan J Maghzal; Helen J Ball; Gavin McKenzie; T Michael De Silva; Roland Stocker; Christopher G Sobey
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-02-27       Impact factor: 3.000

Review 4.  Targeting TDO in cancer immunotherapy.

Authors:  Cheng-Peng Yu; Yun-Lei Song; Zheng-Ming Zhu; Bo Huang; Ying-Qun Xiao; Da-Ya Luo
Journal:  Med Oncol       Date:  2017-03-29       Impact factor: 3.064

5.  Regulation of tryptophan 2,3-dioxygenase by HOXA10 enhances embryo viability through serotonin signaling.

Authors:  Leo F Doherty; Hye Eun Kwon; Hugh S Taylor
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-10-19       Impact factor: 4.310

Review 6.  Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?

Authors:  Stefan Löb; Alfred Königsrainer; Hans-Georg Rammensee; Gerhard Opelz; Peter Terness
Journal:  Nat Rev Cancer       Date:  2009-06       Impact factor: 60.716

Review 7.  TDO as a therapeutic target in brain diseases.

Authors:  Cheng-Peng Yu; Ze-Zheng Pan; Da-Ya Luo
Journal:  Metab Brain Dis       Date:  2016-04-13       Impact factor: 3.584

Review 8.  Immunological Relevance of the Coevolution of IDO1 and AHR.

Authors:  Merja Jaronen; Francisco J Quintana
Journal:  Front Immunol       Date:  2014-10-20       Impact factor: 7.561

9.  Tryptophan-2,3-Dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosis.

Authors:  Tobias V Lanz; Sarah K Williams; Aleksandar Stojic; Simeon Iwantscheff; Jana K Sonner; Carl Grabitz; Simon Becker; Laura-Inés Böhler; Soumya R Mohapatra; Felix Sahm; Günter Küblbeck; Toshikazu Nakamura; Hiroshi Funakoshi; Christiane A Opitz; Wolfgang Wick; Ricarda Diem; Michael Platten
Journal:  Sci Rep       Date:  2017-01-24       Impact factor: 4.379

Review 10.  Understanding the role of the kynurenine pathway in human breast cancer immunobiology.

Authors:  Benjamin Heng; Chai K Lim; David B Lovejoy; Alban Bessede; Laurence Gluch; Gilles J Guillemin
Journal:  Oncotarget       Date:  2016-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.